Chronic infection with hepatitis B virus (HBV) affects more than 240 million individuals globally and can lead to serious complications, such as cirrhosis and hepatocellular carcinoma. While universal maternal screening programs and immunoprophylaxis to newborns have greatly reduced mother-to-child-transmission (MTCT), immunoprophylaxis can fail in up to 30% of infants, especially in mothers with high HBV DNA levels and positive HBeAg. As a result, there has been growing support for the initiation of antiviral therapy during late pregnancy in highly viremic women, and this has been shown in a recent randomized controlled trial to be safe and effective in preventing MTCT with antiviral therapy starting at 30-week gestation and in combination with birth-dose HBV immunoglobulin (HBIG) and vaccination followed by completion of the 3-dose vaccine series. Antiviral therapy may also be initiated to improve maternal outcomes, as immunological changes during pregnancy and post-partum can lead to acute liver failure in women. During pregnancy, cell-mediated immunity is suppressed, possibly due to an increase in adrenal corticosteroids, estrogens, and progesterone, thereby allowing the woman to tolerate the semiallogenic fetus. Post-partum, these changes are reversed. As a result, flares of alanine aminotransferase (ALT) and HBV DNA have been reported during pregnancy as well as the initial post-partum period in HBV-infected women. While most hepatic flares are during late trimester, mild and resolve spontaneously, approximately half can occur during second trimester or earlier and severe cases including liver failure have been reported both during pregnancy and postpartum. The American Association for the Study of Liver Diseases (AASLD) guidelines recommend antiviral therapy for pregnant women with HBV DNA >200,000 IU/mL, even in the absence of clinical symptoms, in order to reduce MTCT, and monitoring for ALT flares every 3 months for 6 months when antiviral therapy is discontinued. However, there is no consensus on the management of HBV in women with HBV DNA ≤200,000 IU/mL, women with active hepatic inflammation or advanced fibrosis, or who become pregnant while on therapy. In general, because significant HBV DNA and ALT flares can occur during pregnancy and early post-partum in women with CHB, HBV-infected women should be closely monitored every 4-6 weeks during pregnancy and early post-partum months three and six.